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ABSTRACT 
 
Background: The incidence of cardiovascular events in HIV-infected patients has fallen, although 
modifiable cardiovascular risk factors (CVRF) are not sufficiently well managed in these patients. 
Methods: We identified 81 patients with a history of coronary events from 2 hospitals in Spain to 
evaluate management of CVRF in clinical practice before and after the event.  
Results: The prevalence of coronary events was 2.15%. At the time of the coronary event, CVRF 
were highly prevalent (60.5% hypertension, 48.1% dyslipidemia, 16% diabetes); 12.2%, 23.1%, and 
11.4% of patients requiring therapy for these conditions did not receive it. Other CVRF were not 
routinely assessed. A significant decrease in total cholesterol (P=0.025) and LDL-cholesterol 
(P=0.004) was observed after the event. LDL-cholesterol and HDL-cholesterol were determined in an 
increasing percentage of patients (from 18.5% before treatment to 73% at the last visit); however, the 
percentage of patients who maintained LDL-cholesterol >100 mg/dL remained stable (from 46% to 
41%). The percentage of patients using PI with an unfavorable lipid profile decreased over time. 
Conclusions: The prevalence of heart disease in our cohort was low. Although CVRF were highly 
prevalent in patients with coronary events, a significant decrease in total cholesterol and LDL-
cholesterol was observed after the event. These were associated with more metabolically favorable 
antiretroviral agents. However, many patients did not achieve the recommended objectives in lipid 
parameters. Furthermore, physicians in our setting did not regularly monitor other cardiovascular risk 
factors. More aggressive interventions should be implemented to diminish cardiovascular risk in HIV-
infected patients. 
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RESUM 
 
Introducció: La incidència de les malalties cardiovasculars a pacients infectats per VIH han 
disminuït, encara que els Factors de Risc Cardiovascular modificables (FRCV) no han estat 
suficientment ben gestionades en aquests pacients. 
Mètodes: Vam identificar 81 pacients amb un historial de malalties coronaris de 2 hospitals a 
Espanya per avaluar la gestió dels FRCV a la pràctica clínica abans i després de l’esdeveniment.  
Resultats: La prevalència de les malalties coronaries va ser del 2,15%. A la vegada que la malaltia 
coronaria, els FRCV era molt freqüent (60,5% hipertensió, 48,1% dislipèmia, 16% diabetis); 12.2%, 
23.1%, i 11.4% dels pacients que requerien teràpia per aquestes condicions no la van rebre. Altres 
FRCV no eren determinats rutinàriament. Desprès de la malaltia coronaria es va observar una 
significant disminució en colesterol total (P=0.025) i LDL-colesterol (P=0.004). LDL-colesterol i HDL-
colesterol es van determinar en un percentatge creixent de pacients (del 18.5% abans del tractament 
fins al 73% a la darrera visita); amb tot, el percentatge de pacients amb LDL-colesterol >100 mg/dL 
es va mantenir estable (del 46% al 41%). El percentatge de pacients que van utilitzar PI amb un 
perfil lipídic desfavorable va decréixer en el darrer període.  
Conclusions: La prevalència de les malalties coronaris a la nostra cohort va ser baixa. Encara que 
els FRCV era molt freqüent als pacients amb problemes coronaris, es va observar una significant 
disminució del colesterol total i del LDL-colesterol desprès de la malaltia coronaria. Aquests estaven 
associats amb l’ús d’agents antiretrovirals amb millor perfil metabòlic. Amb tot, molts pacients no van 
aconseguir els objectius recomanats en els paràmetres lipídics. A més, els metges no van 
monitoritzar regularment altres factors de risc cardiovascular. S’hauria d’implementar intervencions 
més agressives per tal de disminuir el risc cardiovascular en pacients infectats per VIH. 
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INTRODUCTION 
 
The increased life expectancy of the HIV-1-infected population means that physicians have recently 
been observing previously unrecognized comorbid conditions and antiretroviral-related complications. 
Atherosclerosis and cardiovascular events, loss of renal function, osteopenia/osteoporosis, and non–
AIDS-defining cancers are some of the emerging conditions observed in large observational cohorts, 
and their incidence seems to be higher than in the general population.1, 2 
 
Several studies, including the Data Collection on Adverse Events of Anti-HIV Drugs (D.A.D.) study, 
have demonstrated an increased rate of premature cardiovascular events, including myocardial 
infarction, in HIV-1-infected individuals.3,4,5 Traditional risk factors have a similar impact on 
cardiovascular disease (CVD) in this population as they do in the general population.6 However, both 
HIV replication and antiretroviral therapy may contribute independently to an increased risk of 
CVD.3,7,8,9,10 Several hypotheses have been formulated to explain premature aging and the high 
incidence of coronary events in these patients. Some mechanisms are related to antiretroviral 
therapy, such as the mitochondrial dysfunction and oxidative stress induced by thymidine 
analogues11,12,13,14 or protease inhibitor (PI)–related dyslipemia14,15,16, while the virus itself contributes 
to increased cardiovascular risk by a chronic inflammatory effect or a direct effect on endothelial and 
other cells.17,18 These factors, together with the increased incidence of traditional cardiovascular risk 
factors in HIV-1-infected patients, could explain the high incidence of coronary events.5,7,19,20.  
 
Encouraging data suggest that the incidence of ischemic heart disease has diminished in HIV-1-
infected patients in recent years21, due to a more aggressive approach to CVD by health 
professionals, better management of risk factors, and the use of new antiretroviral regimens with 
more favorable lipid profiles. However, the number of HIV-1-infected patients who suffer myocardial 
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infarction continues to be higher than in the non-infected population, and optimal control of modifiable 
risk factors, specifically dyslipidemia, is still poor22. 
 
Risk assessment for CVD should be a part of routine HIV care, and interventions to address 
modifiable risk factors should be implemented and evaluated. Such an approach should include 
intervention in the case of laboratory abnormalities and should address other risk factors (smoking, 
lack of exercise, family history of CVD, etc).  
Based on the hypothesis that modifiable cardiovascular risk factors are not sufficiently well managed 
to diminish cardiovascular risk and the rate of coronary events in HIV-1-infected patients, we 
evaluated management of these factors in our clinical practice before and after a coronary event. 
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METHODS 
Study design and population 
We performed a retrospective descriptive study to determine the prevalence of coronary events in a 
Mediterranean cohort of HIV-1-infected patients and to evaluate the management of cardiovascular 
risk factors over time in those patients who had presented a coronary event. 
 
HIV-1-infected patients with a previous coronary event were identified from the database of the HIV 
care unit and cardiology department of two hospitals in Barcelona, Spain (Sant Pau University 
Hospital and Germans Trias i Pujol University Hospital) The database contained information on 3,760 
HIV-1-infected patients.  
 
The inclusion criteria were as follows: definite or probable acute myocardial infarction or re-infarction, 
angina, percutaneous coronary angioplasty/stenting, bypass surgery, target vessel revascularization 
for restenosis, stent thrombosis, and death from coronary disease.   
 
Acute myocardial infarction was defined according to the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes 042 (and all subtypes), 043, 044.9, 079.53, 
and V08. Cases of myocardial infarction were categorized as fatal or non-fatal according to the 
criteria of the World Health Organization Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease Project (MONICA).23 
 
Study objectives and endpoints 
We determined the prevalence of coronary events in our cohort by assessing the number of persons 
per 1000 inhabitants who presented a coronary event between the date of HIV diagnosis and the 
present.  
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To evaluate changes in modifiable coronary risk factors before and after the coronary event, we 
compared the prevalence of modifiable cardiovascular risk factors in the clinical history (metabolic 
abnormalities and antiretroviral combinations) at three time points: before initiating antiretroviral 
therapy, at the time of the coronary event, and after the event (the last available visit).  
 
Finally, we compared the Framingham risk score at the time of the coronary event and the at last 
available visit. 
 
Assessments    
We recorded the following information at the time of the coronary event: sociodemographic features 
(age, gender, race), HIV-related data (time since HIV diagnosis, risk behavior, previous AIDS 
diagnosis defined according to the Centers for Disease Control and Prevention category C,24 time on 
antiretroviral therapy, time on HAART, nadir CD4 T cells, cumulative exposure to antiretroviral drugs 
such as nonnucleoside reverse transcriptase inhibitors [NNRTI], the nucleoside reverse transcriptase 
inhibitor [NRTI] abacavir, and PIs), personal and family history of hypertension, diabetes mellitus, 
dyslipidemia, previous cardiovascular events, nephropathy, body mass index, hepatitis coinfection, 
concomitant therapies (treatment for dyslipidemia, hypertension, and diabetes), smoking, alcohol 
consumption, and lack of exercise.  
 
In addition, at each of the three time points mentioned above, we recorded laboratory data (plasma 
HIV-1 RNA levels, lymphocyte CD4 T-cell count, total cholesterol, low-density lipoprotein [LDL] 
cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, glomerular filtration rate, and 
glucose level) and the Framingham risk score.  Cardiovascular risk was classified according to the 
Framingham score as low (<10%), moderate (10%-20%), or high (≥20%). 
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Detection and evaluation of high blood cholesterol in adults (Adult Treatment Panel III) was defined 
using the criteria of the National Cholesterol Education Program guidelines25; hypertension was 
defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or the need 
for antihypertensive drugs and/or angiotensin converting enzyme inhibitors. Patients were considered 
to have dyslipidemia if they were taking lipid-lowering drugs or when the total cholesterol level was 
>200 mg/dL and/or LDL cholesterol level was >100 mg/dL and/or triglycerides >150 mg/dL.    
 
Statistical analysis  
We assessed the prevalence of coronary events among HIV-1-infected patients. 
Demographic and clinical parameters were expressed as mean (SD), median and interquartile range 
(IQR), or frequency and percentage, as appropriate. 
 
Continuous repeated measurements were compared using the t test, Wilcoxon test, or Friedman test; 
proportions were compared using the McNemar test or Cochran test. 
Univariate P values <0.05 were considered significant. All statistical analyses were performed using 
SPSS software version 15.0.0 (SPSS Inc, Chicago, Illinois, USA). 
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RESULTS 
 
We identified 108 HIV-1-infected patients who had experienced a coronary event. However, 27 were 
excluded from the analysis because they did not fulfill the selection criteria. Finally, data were 
collected for 81 patients from the 3,760 patients in the database (prevalence of 2.15%). 
 
Coronary event 
The coronary event was fatal in 2.5% of the patients analyzed. The most frequent event was acute 
myocardial infarction (82.7%), followed by angor pectoris (12%), and re-infarction or angor following 
acute myocardial infarction (5.3%). Medical treatment was administered during the coronary event in 
86.4% of patients, percutaneous angioplasty in 51.9%, bypass surgery in 3.7%, and vessel 
revascularization for re-stenosis and stent thrombosis in 1.2%. Coronary angiography revealed 
stenosis in 43 (53.1%) patients, with single vessel involvement in 19 (41.9%) and 2 or more vessels 
in 25 (58.1%).  
 
Patient data at the time of the coronary event 
Overall, 86.1% of patients were male and the median age was 48 (40-57) years; 64% were aged 35 
to 55 years and 5.3% were younger than 35 years. The median time from diagnosis of HIV-1-
infection was 14.9 (10.4-19.2) years, median time on antiretroviral treatment was 8 (5-12) years, and 
cumulative exposure to antiretroviral therapy and to protease inhibitors was 12.7 (9.3-16.2) years and 
5 (0.7-8) years, respectively. Table 1 shows the traditional risk factors and the epidemiologic and 
HIV-related characteristics of the patients at the time of the coronary event. 
 
Hypertension was present in 60.5% of patients, dyslipidemia in 48.1%, and diabetes in 16%. Overall, 
12.2%, 23.1%, and 11.4% of patients, respectively, did not receive any treatment to control these 
conditions. 
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The prevalence of smokers in our population was 44%; 16% were ex-smokers. The information in the 
medical records revealed that only 3 patients (3.7%) were questioned about physical exercise and 
that only 1 (1.7%) reported taking regular physical exercise. Twenty-one percent had a family history 
of cardiovascular events. According to the Framingham equation, 8.3% of the patients were defined 
as high-risk.   
 
Changes in modifiable cardiovascular risk factors at the three time points   
Changes in smoking habit, exercise, body mass index, use of lipid-lowering drugs, antihypertensive 
and oral antidiabetic drugs/insulin were not evaluated, since this information was not available in the 
clinical history of several patients, except at the time of the coronary event. Similarly, in most cases it 
was not possible to evaluate variations in Framingham score, as the information necessary to 
calculate the score (eg, determination of HDL-cholesterol levels and blood pressure at the first time 
point, namely, before starting antiretroviral therapy) was not available. Metabolic parameters at the 
three time points are summarized in Table 2. 
 
No significant differences were observed between HDL-cholesterol, triglyceride levels and glycemia. 
Levels of LDL- and HDL-cholesterol were only determined in 18.5% of subjects at the baseline visit 
(previous antiretroviral therapy); 46% of these patients had an LDL-cholesterol level of >100 mg/dL. 
At time of the coronary event, an LDL-cholesterol determination was available for 47% of patients, 
and in 45% this was >100 mg/dL. Finally, at the last available visit (after the coronary event), an LDL-
cholesterol determination was available for 73% of patients, and in 41% this was >100 mg/dL.  
A significant decrease from the time of the coronary event to the last visit was observed in total 
cholesterol (from 182 [50.3] mg/dL to 174 [50.3], P=0.025) and LDL-cholesterol (from 104 [44.8] 
mg/dL to 95 [30.9], P=0.004).  
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Fewer patients are currently taking a PI with an unfavorable lipid profile (21%) than at the time of 
coronary event (31.5%), whereas more metabolically favorable PIs are increasingly used (from 
20.4% at the time of the coronary event to 31% at the last visit). A similar percentage of patients was 
receiving an NNRTI (efavirenz or nevirapine) at the time of the coronary event and at the last visit 
(48.1% and 47.9%) (Table 3).  
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DISCUSSION     
 
The prevalence of coronary events in our cohort of HIV-1-infected subjects was lower than that 
observed by other groups (2.15%). Traditional risk factors for CVD were highly prevalent in patients 
with a history of coronary heart disease at the time of the event, although a significant decrease in 
total and LDL-cholesterol levels were observed after the event. This was associated with the use of 
antiretrovirals with a more favorable lipid profile. Nevertheless, many patients did not achieve the 
recommended objective in lipid parameters. Additionally, during recent years, physicians in our 
setting did not regularly assess control of other cardiovascular risk factors such as smoking, lack of 
exercise, or hypertension. 
 
 HIV-1-infected individuals receiving HAART have a higher risk of ischemic heart disease than the 
general population6,26. Previous studies report incidence rates ranging from 0.032 to 5.9 cases per 
1000 person-years.20,23,26,27 In addition, large observational studies have proved that this increased 
rate of premature cardiovascular events rises progressively with prolonged exposure to antiretroviral 
therapy, particularly in patients on a PI-containing regimen.3,9,11,12,13,15,28,29 
 
Cardiovascular morbidity in the general population is not well documented in Spain, due to the lack of 
exhaustive and reliable data sources. Consequently, it is difficult to know the real prevalence of acute 
myocardial infarction. However, a meta-analysis including 19 studies evaluating cardiovascular and 
cerebrovascular events in our area showed that the prevalence of angina in Spain was about 7%.26,27 
In our HIV-1-infected population, on the other hand, the prevalence of coronary events was very low 
(2.15%). An explanation for this low rate could be the effect of a Mediterranean diet. As well, 
although the search was exhaustive, it could be the possibility that not all patients were recorded due 
to the retrospective design of the study.  
 
 18  
The pathogenic mechanism of premature atherosclerosis in HIV-1-infected individuals has not been 
clearly defined, although it is generally considered a multifactorial process. HIV infection and 
antiretroviral therapy may accelerate atherogenesis10,18,30, as do traditional risk factors. First, a 
chronic systemic inflammatory state, endothelial dysfunction, and prothrombotic state caused by the 
virus itself contribute to the pathogenesis of coronary heart disease17,18,19; therefore, viral 
suppression should be maintained to reduce vascular damage.9,17 The higher prevalence of coronary 
atherosclerosis in young asymptomatic men with long-standing HIV infection in comparison with non-
HIV-1-infected subjects supports the role of the virus.21 Second, although seemingly paradoxical, 
antiretroviral therapy could also increase the risk of CVD3,5,10,12-16,31. Prolonged exposure to PIs is 
associated with an increased risk of myocardial infarction, especially in the case of lopinavir and 
indinavir, 3,31,32 and this can be partly explained by PI-related metabolic changes. Additionally, the 
risk of infarction in individuals recently exposed to abacavir or didanosine was higher than in patients 
not exposed to these agents, although these data are very controversial.3,31 In this case, the 
increased risk would be explained by mechanisms other than metabolic disorders. Moreover, 
antiretroviral-related lipodystrophy, which is frequent in very experienced patients, is often associated 
with proatherogenic metabolic changes.32-35 Nevertheless, the absolute risk of cardiovascular 
complications remains low and must be balanced against the high risk of HIV progression in patients 
who do not receive antiretroviral therapy. Thus, the benefits of antiretroviral therapy clearly outweigh 
any associated risk of antiretroviral-related CVD.3,9   
Finally, traditional cardiovascular risk factors (eg, dyslipidemia, hypertension, insulin resistance, and 
diabetes mellitus) are more common in HIV-1-infected individuals than in the general population, 6,36 
as are smoking, cocaine use, or coinfection with hepatitis C virus, all of which are proatherogenic 
factors. The very high rates of smoking, hypertension, dyslipidemia, and diabetes we observed in our 
group were consistent with those of other cohorts of HIV-1-infected patients with myocardial 
infarction.37 Other authors have also shown the prevalence of cardiovascular risk factors to be high 
among non–HIV-1-infected patients with stable coronary heart disease from Mediterranean 
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countries.38 These data indicate that adequate control of cardiovascular risk factors before the 
coronary event would have reduced the incidence of ischemic events. 
 
Fortunately, the incidence of cardiovascular events in the HIV-1-infected population has fallen in 
recent years,6,21 possibly as a result of more aggressive management of the risk of CVD. 
Administration of new and more potent antiretroviral agents that maintain viral suppression in almost 
all HIV-1-infected patients in our setting has limited the damage of viral replication in the vascular 
system. In addition, changes in antiretroviral combinations containing metabolically more favorable 
drugs are helping to mitigate the consequences of antiretroviral-related metabolic disorders. The 
percentage of patients in our cohort receiving antiretrovirals with a negative effect on lipid metabolism 
has decreased over time, and most patients currently take antiretroviral combinations with a more 
favorable metabolic profile, such as NNRTI- or new PI-containing regimens.  
 
Nevertheless, two urgent concerns emerge from our and previous data. First, many modifiable risk 
factors, mainly metabolic disorders and hypertension, are not sufficiently well managed, even after 
they are diagnosed.22 Surprisingly, in our cohort, the number of patients who were receiving 
treatment for concomitant conditions (lipid-lowering agents, antihypertensive drugs, or antidiabetic 
drugs) was extremely high. Only 11.4% of patients requiring lipid-lowering agents were not treated. 
Similarly, LDL- and HDL-cholesterol were more frequently determined during recent years, indicating 
interest in achieving better control of lipid metabolism. However, treatment was suboptimal in most 
cases, and the desired lipid levels were not reached. Lipid levels improved after the coronary event, 
although almost half (41%) of the patients maintained an LDL-cholesterol level >100 mg/dL after the 
coronary event, a rate that is similar to that before the event. Second, other cardiovascular risk 
factors, such as smoking, hypertension, lack of exercise, and body mass index, are not routinely 
assessed. These data were not available in the clinical histories of most of our patients, reflecting 
poor monitoring of these risk factors in our clinical practice. 
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Better monitoring of metabolic and non-metabolic parameters would help to diminish cardiovascular 
risk in HIV-1-infected individuals. Thus, cardiovascular risk should be assessed on a regular basis, 
especially after initiating or switching antiretroviral treatment. Appropriate lifestyle measures (smoking 
cessation, dietary changes, and aerobic physical exercise) are essential if modifiable risk factors are 
to be reverted. In addition, antiretroviral agents should be switched to design a more metabolically 
favorable combination, especially in high-risk individuals. Finally, if lifestyle modifications and 
switching therapy prove ineffective or cannot be applied, adequate pharmacological treatment of 
dyslipidemia, hyperglycemia, and hypertension should be administered. The fact that our patients are 
attended at least twice per year at clinical centers should make it easier to control risk factors. 
 
The retrospective design of our study did not enable us to determine the real rate of some risk factors 
(eg, smoking, lack of exercise, hypertension, increased LDL-cholesterol levels) and thus evaluate 
changes over time. However, the retrospective nature of the study did provide us with a clear picture 
of clinical practice. In addition, despite performing an exhaustive search, we cannot exclude the 
possibility of coronary events attended at other centers and not reported in our database. A 
prospective study is necessary to determine the real prevalence of coronary events in HIV-1-infected 
patients in our area.  
 
In summary, despite suboptimal monitoring of cardiovascular risk factors in our cohort, we observed 
a low rate of coronary events among HIV-1-infected individuals in our area. However, as this group is 
aging, we expect a progressive increase in the incidence of CVD. Therefore, cardiovascular health 
plans are a priority if this increase is to be curbed. We must monitor CVD to assess the effectiveness 
of such plans. Optimal selection of antiretroviral treatment, together with aggressive management of 
other modifiable risk factors, will diminish cardiovascular risk in HIV-1-infected patients. 
 
 21  
 
REFERENCES 
 
1. Mondy K, Tebas P. Emerging bone problems in patients infected with human 
immunodeficiency virus. Clin Infect Dis 2003; 36(Suppl 2): S101-5. 
2. Palella FJ Jr, Delany KM, Moorman AC, et al. Declining morbidity and mortality among 
patients with advanced human immunodeficiency virus infection. HIV Outpatient Study 
Investigator. N Engl J Med 1998; 338: 853-60. 
3. Worm SW, Sabin C, Weber R, et al for the D:A:D Study Group. Risk of myocardial infarction 
in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 
major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J 
Infec Dis. 2010; 201: 218-330.  
4. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J 
Acquir Immune Defic Syndr. 2003; 33: 506-12. 
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and 
cardiovascular risk factors among patients with human immunodeficiency virus disease. J 
Clin Endocrinol Metab. 2007; 92: 2506-12. 
6. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients 
treated for human immunodeficiency virus infection compared with the general population. 
Clin Infect Dis 2003; 37: 292-9. 
7. Martínez E, Arribas JR, López-Aldeguer, et al. Factors associated with a high cardiovascular 
risk in HIV-infected patients in Spain: a multicenter, nationwide cross-sectional study. 12th 
Conference on Retrovirus and Opportunistic infections. Boston; 22-25 February. 2005. 
Abstract 870. 
8. Dau B and Holodniy M. The Relationship Between HIV Infection and Cardiovascular 
Disease. Curr Cardiol Rev 2008; 4: 203-18. 
 22  
9. Steven van Lelyveld, Gras L, Kesselring A, Zhang S, F de Wolf, Wensing A, and Hoepelman. 
Incomplete Immune Recovery on HAART is Associated with Significantly More 
Cardiovascular Events and a Trend Towards More Non-AIDS-related Malignancies in Dutch 
ATHENA Cohort. 17th CROI 2010, San Francisco US, P337, Abstract 714. 
10. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of 
myocardial infarction. N Engl J Med. 2007; 356: 1723-35. 
11. Hsue Priscilla, Hunt P, Schnell A, et al. Inflammation Is Associated with Endothelial 
Dysfunction among Individuals with Treated and Suppressed HIV infection. 17th CROI 2010, 
San Francisco US, P335, Abstract 708 
12. Bedimo R, Westfall A, Drechsler H, Vidiela G, Tebas P. Abacavir use and risk of acute 
myocardial infarction and cerebrovascular disease in the HAART era. In: 5th International 
AIDS Society Conference; 9-22 July 2009; Cape Town, South Africa. 
13. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of 
nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected 
patients. AIDS 2008; 22: F17-24. 
14. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W and D:A:D Study Group. Use of 
nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected 
patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371: 1417-26. 
15. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk 
of myocardial infarction: a case-control study nested within FHDH ANRS CO4. In: 16th 
Conference of Retroviruses and Opportunistic Infections. Montreal; 8-11 February 2009; 
Canada 
16. A Hill, W Sawyer, B Gazzard. Effects of nucleoside analogues versus ritonavir-boosted 
protease inhibitors (PIs) on lipid levels – analysis of 12 clinical trials in 4,231 antiretroviral 
(ARV)-naïve patients. 14th Annual Conference of the British HIV Association (BHIVA), 
Belfast, Northern Ireland, 23–25 April 2008. P79 
 23  
17. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grispoon SK. Association of Immunologic 
and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System. J Acquir 
Immune Defic Synd. 2010 Sep 8. (Epub ahead of print). 
18. Kuller LH, Tracy RP, Shaten J, Meilahn EN, Relation of C-reactive protein and coronary 
heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. 
Am J Epidemiol 1996; 144: 537-47. 
19. Patel P, Zhao H, Patel L, Peppercorn A, Wannamaker P, Gartland M, and Shaefer M. 
Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in 
Antiretroviral-Naive HIV-1-infected Subjects. 17th CROI 2010, San Francisco US, P332, 
Abstract 702. 
20. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular 
disease in HIV-infected patients over time: The Swiss HIV Cohort Study. HIV Med 2006; 7 
(6): 404-10. 
21. Hurley L, Leyden W, Xu L, et al. Updated Surveillance of Cardiovascular Event Rates among 
HIV-infected and HIV-uninfected Californians, 1996 to 2008. Kaiser Pemanente. 16th CROI 
2009, Montreal, P320, Abstract 710. 
22. Gallego M, Palacios R, Olalla J, Orihuela F, Roldán J, Santos J, Grana M; por la Sociedad 
Andaluza de Enfermedades Infecciosas. LDL-cholesterol levels in a series of HIV-infected 
patients. Med Clin (Barc). 2010 Jul 10; 135(5): 202-4. 
23. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. 
Myocardial infarction and coronary deaths in the World Health Organization MONICA 
Project: registration procedures, event rates, and case-fatality rates in 38 population of 21 
countries in four continents. Circulation 1994: 90 (1): 583-612. 
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV-a infected adults and adolescents. Department of Health and 
Human Services. December 1, 2009; 1-161. Available at: 
 24  
http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed July 14, 
2010. 
25. Executive summary of the third report of The National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97. 
26. Medrano MJ, Boix R, Cerrato E, Ramírez Santa Pau M. Incidence and prevalence of 
ischaemic heart disease and cerebrovascular disease in Spain: a systematic review of the 
literature. Rev Esp Salud Publica v.80 n.1 Madrid. Ene-Feb 2006. 
27. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-
uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44 (12): 1625-
31. 
28. Marrugat J, Elousa R, Marti H. Epidemiología de la cardiopatía isquémica en España: 
estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol 
2002; 55: 337-46. 
29. Odueyungbo A, Thabane L, Mercié P, et al. An Individual Patient Meta-analysis to Study the 
Association between Antiretrovirals and Atherosclerosis. 17th CROI 2010, San Francisco US, 
P334, Abstract 705 
30. Lefevre C, Auclair M, Capel E, et al. Ritonavir and lopinavir boosted with ritonavir induce 
endothelial dysfunction and premature senescence in cultured human coronary artery 
endothelial cells. 17th CROI 2010, San Francisco US, P330, Abstract 699. 
31. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected 
patients in France, relative to the general population. French Hospital Database on HIV-
ANRS CO4. AIDS. 2010 May 15;24 (8):1228-30. 
32. Guaraldi G, Zona S, Orlando G, et al. Visceral Fat but Not General Adiposity Is a Predictor of 
Cardiovascular Disease in HIV-infected Males. 17th CROI 2010, San Francisco US, P333, 
Abstract  
 25  
33. Domingo P, Suárez-Lozano I, Teira R, et al. Dyslipemia and cardiovascular disease risk 
factor management in HIV-1-infected subjects treated with HAART in the Spanish VAVH 
cohort. Open AIDS J. 2008; 2: 26-38.  
34. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular 
risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 49 Suppl 2: S79-85. 
35. Jericó C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalencia de factores 
de riesgo cardiovascular en pacientes con infección por el VIH. Rev Clin Esp. 2006; 206: 
556-9. 
36. De Socio GV, Parruti G, Quirino T, et al. Identifying HIV patients with an unfavorable 
cardiovascular risk profile in the clinical practice: Result from the SIMONE study. J Infect 
2008 Jul; 57(1): 33-40. 
37. Grau M, Bongard V, Fito M, et al. REGICOR, GENES Investigators. Prevalence of 
cardiovascular risk factors in men with stable coronary heart disease in France and Spain. 
Arch Cardiovasc Dis. 2010 Feb; 103 (2): 80-9. 
38. Sabin CA, d’Arminio MA, Friis Moller N, et al. Changes over time in risk factors for 
cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact 
on myocardial infarction. Clin Infect Dis 2008; 46 (7): 1101-10. 
 26  
  
 
 
 
 
 
 
 
 
APPENDIX 
 27  
 
Table 1. Patient Characteristics at the Time of the Coronary Event 
 
 
 
 
Age, years (median [IQR]) 48 (40, 57) 
Patients <35 years (%) 5.3% 
Gender (male) (%) 86.1% 
Body mass index >30 (median [IQR]) 0 
Men who have sex with men (%) 38.6% 
HCV coinfection (%) 4.9% 
HBV coinfection (%) 12.3% 
HIV-related characteristics 
Time since diagnosis of HIV-infection, years (median 
[IQR]) 
14.9 (10.4, 19.2) 
Never exposed to antiretroviral therapy (%) 3.7% 
Cumulative exposure to antiretrovirals (median [IQR]) 12.7 (9.3, 16.2) 
Cumulative exposure to PIs (median [IQR])   5 (0.7, 8) 
Cumulative exposure to NNRTIs (median [IQR])     3 (0.1, 7) 
Cumulative exposure to abacavir (median [IQR]) 0.1 (0, 3.5) 
CD4 cells count/µL (median [IQR]) 224 (89, 422) 
HIV-RNA ≤50 copies/mL (median [IQR]) 
HIV-RNA ≤400 copies/mL (median [IQR]) 
29 (35.8%) 
46 (56.8%) 
Antiretroviral combinations used (%) 
     EFV, FTC, TDF  
     NVP, AZT, 3TC 
     LPV/r, ABC, 3TC 
     IDV, D4T, 3TC 
 
14.8% 
4.9% 
4.9% 
4.9% 
Lipodystrophy (including lipoatrophy) (%) 36.1% 
Cardiovascular risk factors 
Family history of coronary heart disease (%) 17 (20.5%) 
Smoking (%) 36 (44%) 
Cumulative exposure to tobacco smoke, years (mean 
[SD]) 
23 (9.4) 
Hypertension (%) 49 (60.5%) 
Use of antihypertensive treatment (%) 43(87.8%) 
Diabetes mellitus (%) 13 (16%) 
Use of antidiabetic treatment (%) 10 (76.9%) 
Dyslipidemia (%) 44 (48.1%) 
Serum total cholesterol, mg/dL  (median [IQR]) 182 (152, 230) 
Serum HDL-cholesterol, mg/dL  (median [IQR]) 41 (31, 43) 
Serum LDL-cholesterol, mg/dL  (median, [IQR]) 93 (77, 143) 
Serum triglycerides, mg/dL  (median, [IQR]) 168(106, 248) 
Use of lipid-lowering agents (%) 39 (88.6%) 
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Table 2. Changes in Modifiable Cardiovascular Risk Factors and Framingham Score at the Three Time Points of the study   
   Characteristics Before 
starting ARV 
At the time 
of the coronary 
event 
Last 
observation 
P value 
(baseline to 
coronary 
event) 
P value 
(event to 
present) 
Laboratory Data      
CD4, cell/µL (median [IQR])   224 (89, 422) 497 (384, 776) 559 (375, 767) 0.000 0.201 
HIV-RNA, log (median [IQR]) 4.6 (3.6, 5.3) 1.8 (1.4, 2.7) 1.4 (1.3, 1.7) 0.000 0.000 
Serum total cholesterol, mg/dL (median [IQR]) 158(151, 213) 182(152, 230) 174 (147, 205) 0.402 0.025 
Serum HDL-cholesterol, mg/dL (median [IQR]) 41 (31, 43) 42 (35, 54.) 46 (35, 54) 0.155 0.974 
Serum LDL-cholesterol, mg/dL (median [IQR]) 97 (67, 135) 104 (77, 143) 95 (70, 112) 0.721 0.004 
Serum triglycerides, mg/dL (median [IQR]) 151 (106, 204) 168 (106, 248) 142(95, 204) 0.778 0.111 
Glycemia, mg/dL (median [IQR]) 90 (85, 103) 97 (88, 108) 95 (88, 108) 0.040 0.299 
Glomerular filtration rate, mL/min (median [IQR]) 60 (60, 60) 60 (60, 60) 60 (60, 60) 0.317 0.317 
Serum total cholesterol >200 mg/dL (n, %) 18 (48.6) 29 (44.6) 25 (35.2) 0.738 0.265 
Serum HDL-cholesterol <40 mg/dL (n, %) 73 (90.1) 21 (43.6) 25 (39.7) 1.000 0.001 
Serum LDL-cholesterol >100 mg/dL (n, %) 7 (46%) 17 (45%) 25 (41%) - 0.103 
Serum triglycerides >150 mg/dL  (n, %) 15 (40.5) 30 (37) 26 (32.1) 0.238 0.022 
Serum triglycerides >500 mg/dL  (n, %) 1 (2.7) 4 (6.3) 3 (4.1) 0.118 0.193 
Glycemia >110 mg/dL (n, %) 5 (14.7) 15 (22.7) 17 (24.3) 0.052 <0.001 
Framingham <10% (low) (n, %) - 3 (3.7%) - - - 
Framingham 10%-20% (moderate) (n, %) - 8 (66.7) - - - 
Framingham  >20% (high) (n, %) - 1 (8.3) - - - 
 
HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol.  
 
 Table 3. Antiretroviral Treatment According to Family During the Event and at the Last Visit 
Antiretroviral Treatment Event Last Visit 
Protease inhibitors with an unfavorable lipid profile (PI) 
Indinavir  6 (11.1%) 6 (5%) 
Lopinavir /ritonavir  11 (20.4%) 17 (14.3%) 
Fosamprenavir  0 2 (1.7%) 
Protease inhibitors with a favorable lipid profile (PI 2) 
Saquinavir  2 (3.7%) 0 
Atazanavir  6 (11.1%) 19 (16%) 
Darunavir  3 (5.6%) 18 (15.1%) 
Nonnucleoside reverse transcriptase inhibitors 
Nevirapine 11 (20.4%) 34 (28.6%) 
Efavirenz 15 (27.7%) 23 (19.3%) 
Total of patients with PI and 
NNRTI 
54 (100%) 119 (100%) 
Nucleoside reverse transcriptase inhibitor 
Abacavir 25 (33%) 14 (19%) 
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